Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

127
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
127
Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

123
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
123

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Independent prognostic ımpact of perineural ınvasion in breast cancer patients with residual disease after neoadjuvant chemotherapy.

Revista da Associacao Medica Brasileira (1992)·2026
Same author

An integrated host vulnerability score is associated with survival in advanced NSCLC treated with nivolumab: a PET/CT-based real-world study.

BMC pulmonary medicine·2026
Same author

Neurotropism and Therapeutic Targeting of Brain Metastases in Small Cell Lung Cancer.

Cancer research·2026
Same author

Concordance between multidisciplinary tumor board decisions and AI-based recommendations in endometrial cancer: impact of discordance direction on clinical outcomes.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2026
Same author

Ki-67 Dynamics and Biomarker Conversion as Prognostic Factors in Residual Breast Cancer.

Asia-Pacific journal of clinical oncology·2026
Same author

Comparative Real-World Safety Profiles of Fibroblast Growth Factor Receptor Inhibitors: A Pharmacovigilance Study.

Asia-Pacific journal of clinical oncology·2026

Related Experiment Video

Updated: Jul 26, 2025

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.7K

Decrease in estimated glomerular filtration rates in non-small cell lung cancer patients treated with crizotinib.

Yakup Iriagac1, Eyyup Cavdar1, Kubilay Karaboyun1

  • 1Department of Medical Oncology, Faculty of Medicine, Tekirdag Namik Kemal University, Tekirdag, Turkey.

Journal of Cancer Research and Therapeutics
|June 14, 2023
PubMed
Summary

Crizotinib treatment for non-small cell lung cancer can cause a temporary decline in kidney function, as measured by estimated glomerular filtration rate (eGFR). This reduction in eGFR is reversible after discontinuing the drug.

Keywords:
Crizotinibglomerular filtration ratelung cancer

More Related Videos

Using Micro-computed Tomography for the Assessment of Tumor Development and Follow-up of Response to Treatment in a Mouse Model of Lung Cancer
11:31

Using Micro-computed Tomography for the Assessment of Tumor Development and Follow-up of Response to Treatment in a Mouse Model of Lung Cancer

Published on: May 20, 2016

10.8K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.0K

Related Experiment Videos

Last Updated: Jul 26, 2025

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.7K
Using Micro-computed Tomography for the Assessment of Tumor Development and Follow-up of Response to Treatment in a Mouse Model of Lung Cancer
11:31

Using Micro-computed Tomography for the Assessment of Tumor Development and Follow-up of Response to Treatment in a Mouse Model of Lung Cancer

Published on: May 20, 2016

10.8K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.0K

Area of Science:

  • Oncology
  • Nephrology
  • Pharmacology

Background:

  • Crizotinib is a tyrosine kinase inhibitor used for non-small cell lung cancer (NSCLC).
  • Uncertainty exists regarding crizotinib's impact on renal function.
  • This study investigated the adverse effects of crizotinib on kidney function in NSCLC patients.

Purpose of the Study:

  • To evaluate the effect of crizotinib on kidney function in NSCLC patients.
  • To document potential adverse effects on renal parameters.
  • To assess the reversibility of any observed changes in kidney function.

Main Methods:

  • Estimated glomerular filtration rates (eGFR) were calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.
  • Creatinine-based eGFR values were compared pre-treatment and at monthly intervals during treatment.
  • Paired samples t-test and Kaplan-Meier survival analysis were employed.

Main Results:

  • Twenty-six NSCLC patients receiving crizotinib were analyzed.
  • A significant reduction in eGFR was observed after the first month of crizotinib treatment (P < 0.001).
  • The decrease in eGFR was reversible upon treatment discontinuation, with no significant difference compared to pre-treatment levels (P = 0.100).

Conclusions:

  • Crizotinib treatment is associated with a reversible decrease in renal function.
  • The observed decline may be due to renal inflammation or pseudo-decrease from altered creatinine excretion.
  • Non-creatinine-based methods for eGFR calculation may provide more accurate renal function assessment in patients on crizotinib.